<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821545</url>
  </required_header>
  <id_info>
    <org_study_id>Ostovic</org_study_id>
    <nct_id>NCT03821545</nct_id>
  </id_info>
  <brief_title>The Anti-inflammatory Effect of Anesthetics in Abdominal Surgery</brief_title>
  <official_title>The Immunomodulatory Effects of Ketamine and Lidocaine in Abdominal Surgery: Double-Blind, Placebo-Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Dubrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Dubrava</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical studies have shown that IV administration of anesthetics, lidocaine and ketamine&#xD;
      with their anti-inflammatory properties, modulates the acute immune response associated with&#xD;
      surgical tissue injury, and in this manner they are able to reduce postoperative pain.&#xD;
      Lidocaine has anti-inflammatory effects on polymorphonuclear granulocytes, IL-6 and IL-8&#xD;
      cytokines, complement component C3a and IL-1ra in serum. Ketamine produces its&#xD;
      anti-inflammatory effects by reducing CRP and IL-6 in serum and by inhibiting NF-kB, which&#xD;
      regulates gene transcription responsible for the production of proinflammatory factors.&#xD;
&#xD;
      Perioperative combinend IV administration of lidocaine and ketamine could have a more&#xD;
      favorable anti-inflammatory effect compared to anesthetic given alone or with placebo.&#xD;
&#xD;
      To investigate the effects of lidocaine and ketamine in patients undergoing abdominal surgery&#xD;
      on: acute immune response following the level of proinflammatory factors in serum (CRP, IL-6,&#xD;
      IL-8); postoperative pain management; recovery of bowel function; LOS in the ICU and LOHS;&#xD;
      reduced administration of opioids; reduction of total treatment costs; recovery time between&#xD;
      participants undergoing conventional and laparoscopic resection of the colon.&#xD;
&#xD;
      A double-blind, placebo-controlled study will include 120 patients: 60 undergoing&#xD;
      conventional and 60 undergoing laparoscopic resection of the colon. Patients will be randomly&#xD;
      assigned to one of four groups: lidocaine, ketamine, lidocaine-ketamine, and placebo.&#xD;
      Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by&#xD;
      an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be&#xD;
      administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an&#xD;
      infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery. Bolus and continuous placebo&#xD;
      infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned&#xD;
      anesthetics until the end of the surgery.&#xD;
&#xD;
      The intensity of pain will be measured using the VAS score 2 hours and 4 hours following&#xD;
      surgery and every 12 hours the following days. The invetigators will measure the consumption&#xD;
      of opioids during and after surgery, the length of stay in the ICU, where pain control and&#xD;
      analgesics use will be measured, as well as recovery of bowel function. Proinflammatory&#xD;
      markers in serum (CRP, IL-6, IL-8) will be measured before induction of anesthesia, then 12&#xD;
      hours and 36 hours following the completion of surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LOS</measure>
    <time_frame>1-5 days</time_frame>
    <description>Length of stay in the ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>1-30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cost of Hospitalisation</measure>
    <time_frame>1-30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in opioid administration</measure>
    <time_frame>1 day</time_frame>
    <description>Measuring of total opioid consumption during postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of proinflammatory markers</measure>
    <time_frame>1-2 days</time_frame>
    <description>Measuring of proinflammatory markers in serum (CRP, IL-6, IL-8) before induction of anesthesia, then 12 hours and 36 hours following the completion of surgery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Lidocaine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine and Ketamine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (0.9% NaCl) Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.</description>
    <arm_group_label>Lidocaine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.</description>
    <arm_group_label>Ketamine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lidocaine and Ketamine</intervention_name>
    <description>Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.</description>
    <arm_group_label>Lidocaine and Ketamine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (0.9% NaCl)</intervention_name>
    <description>Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.</description>
    <arm_group_label>Placebo (0.9% NaCl) Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective Surgery&#xD;
&#xD;
          -  Expected duration of the operation &gt; 2 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients â‰¤ 18 years of age&#xD;
&#xD;
          -  Patients with history of allergy to local anesthetics&#xD;
&#xD;
          -  Chronic opioid analgesic&#xD;
&#xD;
          -  Patients who are unwilling or unable to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Anti-inflammatory Effect of Anesthetics in Abdominal Surgery</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>January 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Dubrava</investigator_affiliation>
    <investigator_full_name>Helena Ostovic</investigator_full_name>
    <investigator_title>Helena Ostovic MD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anti-Inflammatory Effect</keyword>
  <keyword>Surgical Stress</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Abdominal Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

